NSCLC

Cancer

Discovery of BLU-945 Brings Hope to EGFR-Positive NSCLC Patients

Mutations in the epidermal growth factor receptor (EGFR) kinase domain are the oncogenic drivers of this adenocarcinoma. Tyrosine kinase inhibitors (TKIs), developed over the last two decades, targeting EGFR mutations, […]

Latest treatment for non-small cell lung cancer.

Latest treatment for non-small cell lung cancer.

The prognosis of patients with early lung cancer is better, but many patients with lung cancer are diagnosed with advanced stage, and the overall five-year survival rate is only about […]